The Risk of Hypothyroidism With the Use of GLP ‐1 Receptor Agonists in Saudi Arabia

Documenti analoghi

• Real‐World Evidence of Indapamide‐Induced Rhabdomyolysis: A Retrospective Analysis of Electronic Health Records
  di: Raseel Alroba, et al.
  Pubblicazione: (2024)
• Prevalent‐New User Design for Biosimilar Safety Using Saudi Real‐World Data
  di: Ohoud Almadani, et al.
  Pubblicazione: (2026)
• Glucagon‐Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network
  di: Mitchell M. Conover, et al.
  Pubblicazione: (2025)
• Assessing Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Incidence of Major Adverse Cardiovascular Events: A Retrospective Cohort Study
  di: Aljoharah M. Algabbani, et al.
  Pubblicazione: (2025)
• Comparative Safety of Glucagon‐Like Peptide 1 Receptor Agonists ( GLP ‐1‐ RAs ) in Type 2 Diabetes and Chronic Weight Management: A Real‐World Data Study
  di: Sarah Ruth Hurwitz, et al.
  Pubblicazione: (2025)